{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:39:22Z","timestamp":1777325962903,"version":"3.51.4"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.phrs.2026.108117","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:42:46Z","timestamp":1769672566000},"page":"108117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on \u201cPlasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: A long-term prospective longitudinal study\u201d"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7327-1189","authenticated-orcid":false,"given":"Shanshan","family":"Ru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108117_bib1","article-title":"Plasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: a long-term prospective longitudinal study","author":"Garai","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108117_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108117_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000450","article-title":"Thymectomy lowers the myasthenia gravis biomarker miR-150-5p","volume":"5","author":"Molin","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.phrs.2026.108117_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","article-title":"Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies","volume":"5","author":"Pritchard","year":"2012","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108117_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/CIRCRESAHA.111.300539","article-title":"Circulating microRNAs as novel biomarkers for platelet activation","volume":"112","author":"Willeit","year":"2013","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108117_bib6","doi-asserted-by":"crossref","first-page":"8779","DOI":"10.1038\/s41467-025-63750-2","article-title":"Platelet activation plays a pro-inflammatory role in myasthenia gravis","volume":"16","author":"Wen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108117_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fimmu.2019.00539","article-title":"Causes and consequences of miR-150-5p dysregulation in myasthenia gravis","volume":"10","author":"Cron","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:59:24Z","timestamp":1777323564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826000320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":7,"alternative-id":["S1043661826000320"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108117","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on \u201cPlasma miR-150-5p as a biomarker for immunosuppressive therapy response in acetylcholine receptor positive myasthenia gravis: A long-term prospective longitudinal study\u201d","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108117"}}